Department of Blood Purification, Tokyo Women's Medical University, Tokyo 162-8666, Japan.
Department of Nephrology, Tokyo Women's Medical University, Tokyo 162-8666, Japan.
Nutrients. 2021 May 14;13(5):1670. doi: 10.3390/nu13051670.
A series of problems including osteopathy, abnormal serum data, and vascular calcification associated with chronic kidney disease (CKD) are now collectively called CKD-mineral bone disease (CKD-MBD). The pathophysiology of CKD-MBD is becoming clear with the emerging of αKlotho, originally identified as a progeria-causing protein, and bone-derived phosphaturic fibroblast growth factor 23 (FGF23) as associated factors. Meanwhile, compared with calcium and parathyroid hormone, which have long been linked with CKD-MBD, phosphate is now attracting more attention because of its association with complications and outcomes. Incidentally, as the pivotal roles of FGF23 and αKlotho in phosphate metabolism have been unveiled, how phosphate metabolism and hyperphosphatemia are involved in CKD-MBD and how they can be clinically treated have become of great interest. Thus, the aim of this review is reconsider CKD-MBD from the viewpoint of phosphorus, its involvement in the pathophysiology, causing complications, therapeutic approach based on the clinical evidence, and clarifying the importance of phosphorus management.
一系列问题,包括骨病、异常血清数据和与慢性肾脏病(CKD)相关的血管钙化,现在统称为 CKD 矿物质骨病(CKD-MBD)。随着 αKlotho 的出现,一种最初被认为是导致早衰的蛋白质,以及骨源成纤维细胞生长因子 23(FGF23)作为相关因素,CKD-MBD 的病理生理学变得越来越清晰。同时,与长期以来与 CKD-MBD 相关的钙和甲状旁腺激素相比,由于其与并发症和结局的关联,磷酸盐现在引起了更多的关注。顺便说一句,由于 FGF23 和 αKlotho 在磷酸盐代谢中的关键作用已经被揭示,磷酸盐代谢和高磷酸盐血症如何参与 CKD-MBD 以及它们如何在临床上得到治疗已经成为人们极大的兴趣。因此,本综述的目的是从磷的角度重新考虑 CKD-MBD,包括其在病理生理学、引起并发症、基于临床证据的治疗方法中的作用,以及澄清磷管理的重要性。